Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Killing of Quiescent and Cycling Chronic Myeloid Leukemia CD34+ Cells by Autologous Ex-Vivo Expanded Natural Killer Cells Is Enhanced by Bortezomib Treatment.

Agnes S.M. Yong, MD, PhD, Nicole Stephens, BS, Keyvan Keyvanfar, BS, Bipin N. Savani, MD, Rhoda Eniafe, BS, Maria Berg, BS, Elaine M. Sloand, MD, Richard Childs, MD, A. John Barrett, MD

Blood (2010) 116 (21): 3395.

https://doi.org/10.1182/blood.V116.21.3395.3395

Published: 2010

Journal Articles

In Chronic Myeloid Leukemia Cytotoxic T Cell Responses to BMI-1 Protein Correlate with Higher Expression of BMI-1 in Leukemia Progenitors, and May Contribute to Improved Outcome After Allogeneic Stem Cell Transplantation.

S. M. Agnes Yong, MD, PhD, Nicole Stephens, BS, Bipin N. Savani, MD, Yixin Li, PhD, Rhoda Eniafe, BS, Keyvan Keyvanfar, BS, Roger J Kurlander, MD, Katayoun Rezvani, MD, PhD, A. John Barrett, MD

Blood (2009) 114 (22): 192.

https://doi.org/10.1182/blood.V114.22.192.192

Published: 2009

Journal Articles

A Reduced Rate of Leukaemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for Acute Myeloid Leukaemia but Not Other Haematological Malignancies Is Associated with Donor KIR Genes 2DL5A, 2DS1 and 3DS1.

Kate Stringaris, MD, FRCPath, Sharon Adams, Marcela Uribe, Rhoda Eniafe, BS, Colin Wu, Bipin N. Savani, MD, A. John Barrett, MD

Blood (2009) 114 (22): 2282.

https://doi.org/10.1182/blood.V114.22.2282.2282

Published: 2009

Journal Articles

The Response to Repeated Vaccination with PR1 and WT1 Peptides Admixed in Montanide Adjuvant Is Transient and Fails to Induce Sustained Anti-Leukemia Responses in Patients with Myeloid Malignancies.

Katayoun Rezvani, MD, PhD, Agnes S. M. Yong, MD, PhD, Stephan Mielke, Behnam Jafarpour, Bipin N. Savani, MD, Quan Le, Rhoda Eniafe, BS, Carol Boss, Roger J Kurlander, MD, A. John Barrett, MD

Blood (2009) 114 (22): 4096.

https://doi.org/10.1182/blood.V114.22.4096.4096

Published: 2009

Journal Articles

Ex vivo characterization of polyclonal memory CD8 + T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia

Katayoun Rezvani, Agnes S. M. Yong, Abdul Tawab, Behnam Jafarpour, Rhoda Eniafe, Stephan Mielke, Bipin N. Savani, Keyvan Keyvanfar, Yixin Li, Roger Kurlander, A. John Barrett

Blood (2009) 113 (10): 2245–2255.

https://doi.org/10.1182/blood-2008-03-144071

Published: 2009

Includes: Supplemental data

Journal Articles

Primitive quiescent CD34 + cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib

Agnes S. M. Yong, Keyvan Keyvanfar, Nancy Hensel, Rhoda Eniafe, Bipin N. Savani, Maria Berg, Andreas Lundqvist, Sharon Adams, Elaine M. Sloand, John M. Goldman, Richard Childs, A. John Barrett

Blood (2009) 113 (4): 875–882.

https://doi.org/10.1182/blood-2008-05-158253

Published: 2009

Journal Articles

The Level of Minimal Residual Disease in Primitive Progenitor Cells from CML Patients after Allogeneic Stem Cell Transplantation Is Higher Than after Treatment with Tyrosine Kinase Inhibitors.

Agnes S. M. Yong, MD, PhD, Keyvan Keyvanfar, BS, Rhoda Eniafe, BS, Bipin N. Savani, MD, Katayoun Rezvani, MD, PhD, Aarthi Shenoy, MD, Eleftheria K. Koklanaris, BSN, Laura Musse, MSN, Theresa Donohue, MS, Quan Le, MD, PhD, John M. Goldman, MD, A. John Barrett, MD

Blood (2008) 112 (11): 1107.

https://doi.org/10.1182/blood.V112.11.1107.1107

Published: 2008

Journal Articles

Ex-Vivo Characterization of Polyclonal Memory CD8+ T-Cell Responses to PRAME-Specific Peptides in Patients with Acute Leukemia and Chronic Myeloid Leukemia

Katayoun Rezvani, MD, PhD, Agnes S. M. Yong, MBBCH, PhD, Abdul Tawab, PhD, Behnam Jafarpour, MD, Rhoda Eniafe, Stephan Mielke, MD, Bipin N. Savani, MD, Keyvan Keyvanfar, Li Yixin, PhD, Roger Kurlander, MD, A. John Barrett, MD

Blood (2008) 112 (11): 2910.

https://doi.org/10.1182/blood.V112.11.2910.2910

Published: 2008

Journal Articles

Human Neutrophil Elastase Stimulating CD4+ and CD8+ T Cells Is a Potential Protein Vaccine for Leukemia Patients with Diverse HLA Types.

Quan Le, MD, PhD, J. Joseph Melenhorst, PhD, Nancy Hensel, Rhoda Eniafe, A. John Barrett, MD

Blood (2007) 110 (11): 1807.

https://doi.org/10.1182/blood.V110.11.1807.1807

Published: 2007

Journal Articles

Primitive Quiescent CD34+ Cells in Chronic Myeloid Leukemia Are Targeted by In Vitro Expanded Allogeneic Natural Killer Cells, Which Are Functionally Enhanced by Bortezomib Treatment.

Agnes S.M. Yong, MD, PhD, Keyvan Keyvanfar, BS, Nancy Hensel, BS, Rhoda Eniafe, BS, Bipin N. Savani, MD, Maria Berg, BS, Andreas Lundqvist, PhD, Elaine M. Sloand, MD, John M. Goldman, MD, Richard W. Childs, MD, A. John Barrett, MD

Blood (2007) 110 (11): 1008.

https://doi.org/10.1182/blood.V110.11.1008.1008

Published: 2007

Journal Articles

High PR3 or ELA2 expression by CD34 + cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide–driven graft-versus-leukemia effects

Agnes S. M. Yong, Katayoun Rezvani, Bipin N. Savani, Rhoda Eniafe, Stephan Mielke, John M. Goldman, A. John Barrett

Blood (2007) 110 (2): 770–775.

https://doi.org/10.1182/blood-2007-02-071738

Published: 2007

Journal Articles

Cytotoxic T Lymphocyte Responses to PR1 Peptide in Chronic Myeloid Leukemia Patients Inversely Correlate with Proteinase 3 and Elastase Expression but Donor PR1 Responses Determine Survival after Stem Cell Transplantation.

Agnes S.M. Yong, MD, PhD, Katayoun Rezvani, MD, PhD, Bipin N. Savani, MD, Rhoda Eniafe, BS, Stephan Mielke, MD, John M. Goldman, MD, A. John Barrett, MD

Blood (2006) 108 (11): 3697.

https://doi.org/10.1182/blood.V108.11.3697.3697

Published: 2006

Journal Articles

Hematopoietic Stem Cells and Primitive Progenitors Express Leukemia-Associated Antigens That May Be Targets for Graft-Versus-Leukemia Effect or for Vaccine-Based Immunotherapy in Chronic Myeloid Leukemia.

Agnes S.M. Yong, MD, PhD, Keyvan Keyvanfar, BS, Rhoda Eniafe, BS, Bipin N. Savani, MD, Elaine M. Sloand, MD, John M. Goldman, MD, A. John Barrett, MD

Blood (2006) 108 (11): 2125.

https://doi.org/10.1182/blood.V108.11.2125.2125

Published: 2006

NARROW

Killing of Quiescent and Cycling Chronic Myeloid Leukemia CD34+ Cells by Autologous Ex-Vivo Expanded Natural Killer Cells Is Enhanced by Bortezomib Treatment.

In Chronic Myeloid Leukemia Cytotoxic T Cell Responses to BMI-1 Protein Correlate with Higher Expression of BMI-1 in Leukemia Progenitors, and May Contribute to Improved Outcome After Allogeneic Stem Cell Transplantation.

A Reduced Rate of Leukaemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for Acute Myeloid Leukaemia but Not Other Haematological Malignancies Is Associated with Donor KIR Genes 2DL5A, 2DS1 and 3DS1.

The Response to Repeated Vaccination with PR1 and WT1 Peptides Admixed in Montanide Adjuvant Is Transient and Fails to Induce Sustained Anti-Leukemia Responses in Patients with Myeloid Malignancies.

Ex vivo characterization of polyclonal memory CD8 + T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia

Primitive quiescent CD34 + cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib

The Level of Minimal Residual Disease in Primitive Progenitor Cells from CML Patients after Allogeneic Stem Cell Transplantation Is Higher Than after Treatment with Tyrosine Kinase Inhibitors.

Ex-Vivo Characterization of Polyclonal Memory CD8+ T-Cell Responses to PRAME-Specific Peptides in Patients with Acute Leukemia and Chronic Myeloid Leukemia

Human Neutrophil Elastase Stimulating CD4+ and CD8+ T Cells Is a Potential Protein Vaccine for Leukemia Patients with Diverse HLA Types.

Primitive Quiescent CD34+ Cells in Chronic Myeloid Leukemia Are Targeted by In Vitro Expanded Allogeneic Natural Killer Cells, Which Are Functionally Enhanced by Bortezomib Treatment.

High PR3 or ELA2 expression by CD34 + cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide–driven graft-versus-leukemia effects

Cytotoxic T Lymphocyte Responses to PR1 Peptide in Chronic Myeloid Leukemia Patients Inversely Correlate with Proteinase 3 and Elastase Expression but Donor PR1 Responses Determine Survival after Stem Cell Transplantation.

Hematopoietic Stem Cells and Primitive Progenitors Express Leukemia-Associated Antigens That May Be Targets for Graft-Versus-Leukemia Effect or for Vaccine-Based Immunotherapy in Chronic Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only